^
Association details:
| Biomarker: | BRCA wild-type |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + ART12 (Bacteria replacement, Microbiome modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2608 / 21 - Pre-clinical evaluation of small molecule CHK2 inhibitor, ART-122 combined with olaparib in BRCA wild type tumors
Published date:
03/09/2022
Excerpt:
The combination of ART-122 and Olaparib demonstrated a synergistic effect in BRCA wild-type ovarian and breast tumor cell lines. In the mouse xenograft model, the CHK2 inhibitor ART-122 sensitized BRCA1/2 wild-type tumor cells MDA-MB-231 to olaparib treatment.
